Clinical trials: Chronic Airflow Obstruction
COPD
Effects of Manual Diaphragmatic Technique Versus Lateral Coastal Breathing Exercises Among COPD Patients.
Chronic obstructive pulmonary disease is a common, preventable as well treatable disorder, which is also one of the main reasons of high mortality and morbidity characterized by irreversible airflow limitation and has respiratory…
- Trial name
- NCT06844994
- Testing
- Manual Diaphragmatic Technique, Lateral Coastal Breathing
- Where
- Pakistan
- Volunteers
- 58 people
- Sponsor
- Riphah International University
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies.
- Trial name
- NCT01437397
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate
- Where
- 222 sites in United States, Australia and 2 more
- Volunteers
- 1,692 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
The purpose of this extension study is to evaluate the long-term safety, tolerability, and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT00970268
- Testing
- Aclidinium bromide
- Where
- 83 sites in United States, Canada
- Volunteers
- 291 people
- Sponsor
- AstraZeneca
COPD
Complexity of the Airflow in COPD
Recently, there has been a growing interest in the study of nonlinear dynamics as a methodology for complementary analysis to characterize the respiratory pattern. These methods are well established in studies of heart rate.
- Trial name
- NCT01888705
- Where
- Brazil
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Rio de Janeiro State University
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)
The purpose of this study is to evaluate the safety, tolerability and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe, stable chronic obstructive pulmonary disease.
- Trial name
- LAS-MD-35 (NCT01044459)
- Testing
- Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg
- Where
- 113 sites in United States, Canada
- Volunteers
- 605 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
The purpose of this study is to evaluate the efficacy of this multicenter, randomized, double-blind, placebo-controlled, 4-period, incomplete-block crossover, dose-ranging study comparing 2 fixed dose combinations (FDCs) of…
- Trial name
- LAC-MD-27 (NCT01049360)
- Testing
- Aclidinium 400 μg / Formoterol 12 μg, Aclidinium 400 μg / Formoterol 6 μg, Aclidinium 400 μg
- Where
- 20 sites in United States
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
- Trial name
- NCT00683722
- Testing
- Prochymal™
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Mesoblast, Inc.
Chronic Obstructive Pulmonary Disease
SCOPE-Study: Salzburg Chronic Obstructive Pulmonary Disease- Exercise and Oxygen Study
Chronic obstructive pulmonary disease (COPD) is number four of the leading causes of death in the USA and Europe. Moreover, among the top five causes of death, this disease is the only one with increasing mortality rates.
- Trial name
- SCOPE (NCT01150383)
- Testing
- Physical exercise training with supplemental oxygen, Physical exercise training with "room air supplementation"
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Paracelsus Medical University
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic
In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency
The Breathe NIOV™ System will reduce the work of breathing in subjects with chronic respiratory insufficiency who require long-term oxygen therapy (LTOT).
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
- Trial name
- NCT01347931
- Testing
- NIOV System, Standard Oxygen Cannula
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Breathe Technologies, Inc.
Chronic Obstructive Pulmonary Disease
Feel Breathe, Restriction Device Ventilatory Nasal (COPD)
FEELBREATHE®, a nasal ventilatory restriction device, used during an exercise test in treadmill produces changes on breathing efficiency in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- BreatheCOPD (NCT01695265)
- Testing
- Exercie oronasal breathing (ONB), Exercie nasal breathing through the FB
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- University of Cadiz
COPD
Cervical Nags Effect on Accessory Muscles
The aim of this work is to record changes on accessory muscles especially sternocleidomastoid and scalene after applying cervical NAGs in COPD patients.
- Trial name
- NCT06736145
- Testing
- Traditional Physical Therapy, Mulligan Glides
- Where
- Pakistan
- Volunteers
- 36 people
- Sponsor
- Riphah International University
COPD (Chronic Obstructive Pulmonary Disease)
Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm
Under-diagnosis of Chronic Obstructive Pulmonary Disease (COPD) is prevalent, with an estimated 75% of adults suffering from COPD in the US, without clinical recognition.
- Trial name
- COPD (NCT07223749)
- Where
- United States
- Volunteers
- 425 people
- Sponsor
- Wake Forest University Health Sciences
Chronic Obstructive Pulmonary Disease
Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients
To demonstrate the efficacy of ROX AC1 (with respect to exercise capacity and quality of life) in patients with COPD.
- Trial name
- NCT00832611
- Testing
- Arteriovenous Fistula (ROX AC1)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- ROX Medical, Inc.
Chronic Obstructive Lung Disease, Airflow Obstruction
Screening for Obstructive Respiratory Disorders in the General Population During the "Mai Poumon 2026" Prevention Campaign: Prevalence and Impact on the Care Pathway
Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD…
- Trial name
- Mai Poumons 26 (NCT07575880)
- Testing
- Spirometry
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier de la côte Basque
Chronic Obstructive Pulmonary Disease
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01437540
- Testing
- Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
- Where
- 137 sites in United States
- Volunteers
- 590 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction
The main purpose of this study is to determine whether pharmacological treatment with N-acetylcysteine improves central and peripheral cardiorespiratory control and physical capacity in COPD patients with mild-to-moderate airflow…
- Trial name
- NCT02579772
- Testing
- N-acetylcysteine
- Volunteers
- 13 people
- Sponsor
- Queen's University
Pulmonary Disease, Chronic Obstructive
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs.
- Trial name
- NCT00706914
- Testing
- Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Once-daily formoterol fumarate
- Where
- 40 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the safety and efficacy of a range of oglemilast doses. The study will be 14 weeks in duration. All patients meeting the eligibility criteria will be randomized to one of three doses of oglemilast or…
- Trial name
- NCT00671073
- Testing
- Oglemilast
- Where
- 47 sites in United States
- Volunteers
- 427 people
- Sponsor
- Forest Laboratories
Pulmonary Disease, Chronic Obstructive
Sputum Colour Charts to Guide Antibiotic Self-treatment of Acute Exacerbation of COPD (Colour COPD)
The primary objective of this study is to determine if a sputum colour chart can aid patient self-management of COPD exacerbations, such that use of the chart is non-inferior to usual care with respect to hospital admissions.
- Trial name
- NCT04705233
- Testing
- sputum colour chart
- Where
- United Kingdom
- Volunteers
- 2,954 people
- Sponsor
- University of Birmingham